Influence of ginsenoside Rh1 and F1 on human cytochrome P450 enzymes

被引:52
作者
Liu, Y
Ma, H
Zhang, JW
Deng, MC
Yang, L
机构
[1] Chinese Acad Sci, Dalian Inst Chem Phys, Lab Pharmaceut Resource Discovery, Dalian 116023, Peoples R China
[2] Chinese Acad Sci, Grad Sch, Dalian, Peoples R China
[3] Liaoning Normal Univ, Coll Life Sci, Liaoning, Peoples R China
关键词
ginsenoside; hydrolysis products; systemic circulation; cytochrome; P450;
D O I
10.1055/s-2005-873197
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
For an oral herbal medicine, the components that can enter the systemic circulation may be the really effective components. In the present study, the effects on the human cytochrome P450 activities of ginsenoside Rb-1 and two hydrolysis products of 20(S)protopanaxatriol ginsenosides in humans, namely ginsenoside Rb-1 and F-1, which may reach the systemic circulation after oral administration of ginseng extract, were evaluated. Our results showed that Rb-1 exhibited no marked effects on the activities of human cytochrome P450, whereas Rh-1 and F, exhibited competitive inhibition of the activity of CYP3A4 with K-i values of 57.7 +/- 9.6 mu M and 67.8 +/- 16.2 mu M, respectively. F-1 also exhibited a weak- er inhibition of the activity of CYP2D6. Rh, exhibited a weak stimulation rather than an inhibition of the activity of CYP2E1. The degradation of ginsenosides in the gastrointestinal tract may play an important role in the ginseng-associated drug-drug interactions, but the effects might be not due to Rh-1 and F-1.
引用
收藏
页码:126 / 131
页数:6
相关论文
共 30 条
  • [1] High-throughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism
    Ansede, JH
    Thakker, DR
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (02) : 239 - 255
  • [2] Ginseng pharmacology - Multiple constituents and multiple actions
    Attele, AS
    Wu, JA
    Yuan, CS
    [J]. BIOCHEMICAL PHARMACOLOGY, 1999, 58 (11) : 1685 - 1693
  • [3] The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective
    Bjornsson, TD
    Callaghan, JT
    Einolf, HJ
    Fischer, V
    Gan, L
    Grimm, S
    Kao, J
    King, SP
    Miwa, G
    Ni, L
    Kumar, G
    McLeod, J
    Obach, RS
    Roberts, S
    Roe, A
    Shah, A
    Snikeris, F
    Sullivan, JT
    Tweedie, D
    Vega, JM
    Walsh, J
    Wrighton, SA
    [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (07) : 815 - 832
  • [4] Hepatic metabolism of diclofenac:: Role of human CYP in the minor oxidative pathways
    Bort, R
    Macé, K
    Boobis, A
    Gómez-Lechón, MJ
    Pfeifer, A
    Castell, J
    [J]. BIOCHEMICAL PHARMACOLOGY, 1999, 58 (05) : 787 - 796
  • [5] In vitro effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1
    Chang, TKH
    Chen, J
    Benetton, SA
    [J]. DRUG METABOLISM AND DISPOSITION, 2002, 30 (04) : 378 - 384
  • [6] Estabrook R, 1999, Mol Aspects Med, V20, P5
  • [7] Herb-drug interactions: Review and assessment of report reliability
    Fugh-Berman, A
    Ernst, E
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (05) : 587 - 595
  • [8] Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans
    Gurley, BJ
    Gardner, SF
    Hubbard, MA
    Williams, DK
    Gentry, WB
    Cui, Y
    Ang, CYW
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (03) : 276 - 287
  • [9] Harkey MR, 2001, AM J CLIN NUTR, V73, P1101
  • [10] Role of human intestinal Prevotella oris in hydrolyzing ginseng saponins
    Hasegawa, H
    Sung, JH
    Benno, Y
    [J]. PLANTA MEDICA, 1997, 63 (05) : 436 - 440